SLC5A2 and type 2 diabetes mellitus: In addition, the sodium/glucose cotransporter 2 (SGLT2) inhibitor canagliflozin, which has recently been approved for treating type 2 diabetes, also showed effects of indirectly activating AMPK [88] and improving the metabolic profile and cytokines [89].